The short answer

Yes — a medical device startup can fund a large share of its early engineering with NIH grant money, and none of it costs equity. The main door is the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) program, which reserves a set share of the agency's extramural research budget for small US companies. Because device development is longer and more documentation-heavy than consumer product work, non-dilutive money is worth more to a medtech founder than to almost anyone else: it buys you the regulatory groundwork that investors are reluctant to pay for.

Why medtech needs this money more than other categories

A medical device does not finish at a working prototype. Before it touches a patient you need a documented design history, biocompatibility and electrical safety testing where applicable, verification and validation evidence, a risk file, and often clinical data. Medical-grade components and materials cost more and take longer to source, and swapping a supplier mid-project can force retesting. Anyone who budgets a regulated device like a consumer gadget discovers the gap at the most expensive possible moment — see what medical device development actually costs and how the FDA clearance process works.

Grant money is unusually well matched to this profile, because the work reviewers want funded — feasibility studies, bench testing, animal or human studies, verification protocols — is exactly the work that has to happen anyway.

The NIH funding paths worth knowing

SBIR Phase I

A feasibility award. You are proving that the core technical premise works and that the risk profile is understood, not shipping a product. Awards are typically in the low-to-mid six figures over roughly six months to a year. Budget caps are adjusted periodically, so read the current solicitation rather than a summary. Mechanics are covered in how to put an SBIR application together.

SBIR Phase II

The development award, usually in the seven figures over about two years, for companies that met their Phase I aims. This is where real design work, verification testing, and regulatory strategy get funded. The distinction matters a lot for planning — see Phase I vs Phase II.

Fast-Track and Direct to Phase II

NIH allows a combined Phase I/Phase II submission (Fast-Track), and for technologies whose feasibility has already been demonstrated with other funding, a Direct to Phase II application. Direct to Phase II is genuinely useful for device companies that self-funded a working prototype — but the feasibility evidence has to be documented, not asserted.

STTR

Structurally similar to SBIR, but it requires a formal partnership with a research institution that performs a defined minimum share of the work. If your device originated in a university lab, or you need clinical or animal facilities you cannot build, STTR is often the better fit. The differences are laid out in SBIR vs STTR.

Beyond NIH

Device-relevant non-dilutive money also sits at NSF, the Department of Defense medical research programs, and state-level matching or commercialization funds that top up a federal award. Many founders assemble a stack rather than a single grant.

Pick the institute before you write anything

NIH is not one funder. It is a set of institutes and centers, each with its own priorities, study sections, and program officers. A cardiovascular monitor and a rehabilitation device belong to different institutes with different reviewer cultures. Two practical steps:

  • Search the public database of previously funded awards for projects near yours, and note which institute funded them.
  • Email the relevant program officer with a short summary before you write. This conversation is normal, encouraged, and routinely changes the framing of an application for the better.

What reviewers reward in a device application

  • A defined clinical problem with a defined user. Not "improves outcomes" — which outcome, in which population, measured how.
  • Specific aims that can pass or fail. Each aim needs a quantitative success criterion. Vague aims are the most common reason a technically good idea scores badly.
  • A credible regulatory path. Name the likely device classification and route, and say what evidence it demands. Reviewers do not expect clearance; they expect that you know what stands between you and it.
  • A team that can execute. A solo founder with no engineering or clinical depth is a scoring risk. Named consultants, an engineering partner, and clinical collaborators fix this.
  • A commercialization story. Who pays, through which channel, and why the product survives after the grant ends.

Plan around the cash-flow reality

Grants are reimbursement-shaped and slow. Between submission, review, council, and award there are typically several months, and resubmission after a first-round miss is common and not a disgrace. Two consequences for founders: never make payroll depend on a specific award date, and keep the private-capital conversation running in parallel — the tradeoffs are in grants vs investors.

Also understand the strings. Federally funded work carries reporting duties, accounting requirements, and specific rules about the intellectual property created with the money — start with who owns IP from a federal grant. It is workable, but it is not free money with no obligations.

The engineering that makes an application fundable

The strongest applications we see are the ones where the technical plan already exists: a defined architecture, a bench test plan with pass criteria, an identified risk list, and a preliminary bill of materials. That material converts directly into specific aims, a budget with a defensible basis, and a timeline a reviewer believes. It is also the same package you need to actually build the device, which is why doing it first is never wasted effort. Broader context lives in our medical device development section.

Projects House is an engineering firm — not a law firm, an accounting firm, or a regulatory consultancy. This article is educational only. Program rules, budget caps, and eligibility requirements change; confirm everything against the current funding opportunity announcement and get qualified professional advice on grant compliance and regulatory strategy.

Build the technical case, then apply

Projects House develops medical and industrial products for US clients, and we regularly build the engineering half of a grant application: architecture, feasibility testing, risk analysis, test plans, and cost basis. If you are preparing an NIH submission for a device and want the technical narrative to hold up under review, tell us about your project through our contact form.